Lonza Celebrates the 30th Anniversary of Clonetics™ Products, the Pioneer of Primary Cells

Walkersville, MD (USA) / Basel, Switzerland, 16 September 2014 – Lonza is pleased to announce that the Clonetics™ Primary Cells and Media product line is celebrating its 30th anniversary, supporting cell culture research in many areas including angiogenesis, cancer, respiratory and cardiovascular disease, diabetes, renal disorders, and neurobiology.

Clonetics Corporation was founded in 1984 as the pioneer in the human primary cell culture business¹. The company was the first to develop a novel technology that allowed culturing of primary human cells outside of their tissue origin. This was a crucial step forward in the research community as scientists then had the capacity to study tissue-specific characteristics on a cellular level in vitro and to develop more biologically relevant models. Recognizing the importance of this technology, the company was also well funded with many Small Business Innovation Research (SBIR) grants in its early years². After its inception, Clonetics Corporation went through acquisitions that further strengthened the portfolio and its commercial reach in the cell culture market. Today, the Clonetics™ brand is offered by Lonza Walkersville, Inc. and Lonza Cologne GmbH and maintains the leading position in the primary cells market.

Clonetics Corporation first led its primary cell business with select normal cell types supporting dermal, vascular and airway research. Over time, this product line has grown to more than 100+ cell types spanning numerous research areas. Aside from the sheer quantity, the portfolio quality has also expanded to include normal as well as diseased cells from asthma, COPD, diabetes and cystic fibrosis tissue. For each cell type, careful consideration is given to maintain broad donor variety, highest quality control, batch-to-batch consistency, and large-scale production capacity.

Currently, the Clonetics™ brand represents the largest primary cell and media selection on the market. It is well recognized for its outstanding scientific support team and its dedication to consistent, high-performing products.

Find more information on Clonetics™ Primary Cells and Media at www.lonza.com/primary.

To download a high resolution picture of Human Microvascular Endothelial Cells, please click here.

¹http://articles.baltimoresun.com/1995-12-22/business/1995356142_1_cell-culture-culture-business-clonetics
²http://sbirsource.com/sbir/firms/13446-clonetics-corporation
About Lonza Pharma&Biotech – Bioscience Solutions
Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGEr™, Poietics™ and SeaKem®.

About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information
Lonza Cologne GmbH
Marketing Communications and Product PR
Corinna König-Wildförster
Phone: +49 221 99199 464
Fax +49 221 99199 498
pr.cologne@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Phone: +41 61 316 8840
Fax: +41 61 316 9840
constance.ward@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements. Lonza Group Ltd is subject to the listing rules of the SIX Swiss Exchange, which does not have specific requirements equivalent to the listing rules of the SGX-ST for interested person transactions, acquisition and realizations and delisting.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.